Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
FOXO4-DRI (FOXO4) is a anti-aging peptide, at the early research stage in the published literature. Senolytic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4-p53 interaction.
Senolytic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4-p53 interaction.
| Research Status | Early research |
|---|---|
| Half-Life | Unknown |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | Research varies |
D-retro-inverso peptide that interferes with FOXO4-p53 binding in senescent cells, triggering their apoptosis.
Senolytic peptide that selectively induces apoptosis in senescent cells by disrupting FOXO4-p53 interaction.
D-retro-inverso peptide that interferes with FOXO4-p53 binding in senescent cells, triggering their apoptosis.
FOXO4-DRI is at the following stage in the published literature: Early research. All information is for research and educational purposes only.
Reported half-life: Unknown.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.